Asio Capital LLC Buys 622 Shares of Eli Lilly and Company $LLY

Key Points

• Asio Capital LLC has increased its stake in Eli Lilly and Company by 11.8%, now owning a total of 5,914 shares worth approximately $4.61 million.
• Eli Lilly reported an earnings per share (EPS) of $6.31 for the most recent quarter, exceeding analysts' estimates, alongside a 37.6% year-over-year revenue increase to $15.56 billion.
• Institutional investors control 82.53% of Eli Lilly's stock, indicating strong interest from large investment firms in the company.

Asio Capital LLC increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 11.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,914 shares of the company's stock after buying an additional 622 shares during the quarter. Asio Capital LLC's holdings in Eli Lilly and Company were worth $4,610,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Duquesne Family Office LLC boosted its position in Eli Lilly and Company by 52.5% in the first quarter. Duquesne Family Office LLC now owns 94,830 shares of the company's stock worth $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Corient IA LLC purchased a new position in Eli Lilly and Company in the first quarter worth $570,000. LS Investment Advisors LLC boosted its position in Eli Lilly and Company by 1.7% in the first quarter. LS Investment Advisors LLC now owns 2,340 shares of the company's stock worth $1,933,000 after purchasing an additional 40 shares during the last quarter. Cutter Capital Management LP purchased a new position in Eli Lilly and Company in the first quarter worth $14,866,000. Finally, Prism Advisors Inc. purchased a new position in Eli Lilly and Company in the first quarter worth $207,000. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

LLY has been the topic of several research analyst reports. Daiwa Capital Markets cut Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price objective on the stock. in a research report on Sunday, August 17th. Daiwa America cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Leerink Partnrs cut Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 7th. JPMorgan Chase & Co. dropped their price target on Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a research report on Tuesday, September 16th. Finally, DZ Bank raised Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $939.61.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $725.54 on Tuesday. The stock's 50-day simple moving average is $733.42 and its 200 day simple moving average is $765.98. The stock has a market capitalization of $686.69 billion, a price-to-earnings ratio of 47.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.47. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.59 by $0.72. The business had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm's quarterly revenue was up 37.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.92 EPS. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the firm's stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director directly owned 9,402 shares of the company's stock, valued at $6,013,143.12. The trade was a 2.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Daniel Skovronsky bought 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was acquired at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the purchase, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 in the last three months. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.